Shares of Gilead Sciences Inc. GILD advanced 2.46% to $111.11 Thursday, on what proved to be an all-around positive trading ...

This was the stock's second consecutive day of gains.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The investment is expected to create approximately 800 new direct jobs and support over 2,200 indirect jobs by 2028.

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific tariffs.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...